Morocco,South Africa,Australia,China,Hong Kong SAR China,Japan,Korea,New Zealand,Singapore,Thailand,Austria,Belgium,Czech Republic,Denmark,Finland,France,Germany,Hungary,Ireland,Italy,Luxembourg,Netherlands,Norway,Poland,Portugal,Romania,Slovak Republic,Spain,Sweden,United Kingdom,Argentina,Chile,Mexico,Peru,Bahrain,Oman,Qatar,UAE,Canada,Puerto Rico,United States
Protecting your life sciences IP means strengthening your competitive edge and creating value. We provide seamless, cross-border advice to develop, protect, and enforce all forms of life sciences IP rights in an increasingly competitive global market.
Strategic and forward-thinking IP strategies ensure your developments and discoveries remain valuable assets that appreciate over time.
We design strategies that protect and maximize all forms of life sciences IP. From protecting confidential information, securing trade secrets, obtaining critical patent protection and managing global trademark portfolios, to executing joint ventures, collaborations, and strategic licensing agreements, and asserting multi-front patent litigation.
“Whatever IP challenges your business faces, we’ll provide innovative solutions that anticipate risk and maximize opportunity.”
Our clients include a wide range of innovator companies from startups to well-established, multinational public corporations, and premier research universities. They turn to us for guidance in areas ranging from pharmaceuticals, biologics, and nutraceuticals, to medical devices and digital health.
We have a large team of highly experienced lawyers in 40+ countries, many with scientific degrees. They understand the most sophisticated and complex technologies and the nuances of IP and regulatory law – saving valuable time and resources.
Whatever IP challenges your business faces, we’ll provide innovative solutions that anticipate risk and maximize opportunity.
E. Scopics, a French medical technology company specializing in bedside ultrasound imaging solutions, in a patent infringement action pending in the District of Massachusetts.
Dechra Veterinary Products, a global veterinary pharmaceuticals and animal health company, in a patent infringement suit brought by Boehringer Ingelheim Vetmedica, asserting noninfringement and invalidity of the last-to-expire patent covering a method for treating congestive heart failure.
Pfizer, a global biopharmaceutical company, in a series of Hatch-Waxman cases involving its patent portfolio related to Xeljanz XR® and IR tablets and oral solution.
Neurelis, a specialty pharmaceutical company focused on therapies for neurological conditions, as strategic IP counsel managing patent portfolio development, exclusivity strategy, litigation, licensing, and royalty monetization matters for its neuroscience portfolio, including FDA-approved VALTOCO®, and representing the company in a Hatch-Waxman patent infringement action against Padagis relating to its ANDA seeking approval of a generic version of VALTOCO®.
ResMed, a global medical technology company focused on sleep, respiratory, and out-of-hospital care solutions, in multi-patent litigation involving sleep apnea and respiratory care technologies, securing Director Review, patent invalidation, and stays of related actions.
AbbVie and Allergan, global biopharmaceutical companies, in a patent infringement action involving patents covering the glaucoma treatment Lumigan®.
Sentrics, a healthcare technology company focused on communication, engagement, and safety solutions for senior living and healthcare settings, in a patent infringement action involving wireless life-safety communication technology for healthcare settings.
Eli Lilly, a global pharmaceutical company focused on innovative medicines across diabetes, oncology, immunology, and neuroscience, on intellectual property due diligence for acquisitions, collaborations, and licensing transactions involving innovative therapeutic, biotechnology, and AI-enabled drug development assets.
Organon, a global healthcare company focused on women's health, biosimilars, and established medicines, on patent prosecution, Orange Book strategy, patent term extensions, exclusivity, and lifecycle management for VTAMA® (tapinarof) and related pipeline products.
Kyntra Bio (formerly FibroGen), a biotechnology company developing therapies for serious and life-threatening diseases, on strategic patent, licensing, and transactional matters across its anemia and oncology portfolios, including the sale of its Chinese subsidiary and rights to roxadustat to AstraZeneca.
Jazz Pharmaceuticals, a global biopharmaceutical company focused on neuroscience and oncology, on patent prosecution, lifecycle management, market exclusivity strategies, and IP due diligence supporting key therapeutic development programs.
Palvella Therapeutics, a clinical-stage biopharmaceutical company developing therapies for rare genetic skin diseases, on patent and exclusivity strategies that supported the repositioning of its lead clinical candidate, strengthened protection for rare disease programs, and enhanced company value.
Aclaris Therapeutics, a clinical-stage biopharmaceutical company focused on immunology and dermatology therapies, on strategic patent counseling, IP due diligence, and licensing transactions supporting the expansion of its immunology and dermatology pipeline.
Delfi Diagnostics, a biotechnology company focused on blood-based cancer detection and screening technologies, on patent portfolio development, IP diligence, freedom-to-operate analyses, and strategic counseling for its early cancer detection technologies.
Senti Bio, a biotechnology company developing next-generation gene circuit and cell therapies, on worldwide patent prosecution and intellectual property strategy for its gene circuit and cell therapy platform technologies designed to treat oncology and other serious diseases.
GT Biopharma, a clinical-stage immuno-oncology company developing natural killer cell-based therapies, on global patent prosecution, portfolio development, and intellectual property strategy for its proprietary TriKE® natural killer cell engager platform and immuno-oncology pipeline.
